ARTL stock icon

Artelo Biosciences
ARTL

$1.29
4.72%
 

About: Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors and neurotransmitters that form a biochemical communication network in body. It is focused on discovering, licensing, developing, and commercializing treatments that control endocannabinoid systems. The company pursues technologies and programs that offer proprietary approaches to cannabinoid-based therapies, also those derived from the cannabis plant and synthetic cannabinoids, as well as new chemical entities and compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare and orphan disease.

Employees: 6

0
Funds holding %
of 6,702 funds
0
Analysts bullish %
of 3 analysts
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

200% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 0

8% more capital invested

Capital invested by funds: $34.3K [Q4 2023] → $37.2K (+$2.84K) [Q1 2024]

0% more funds holding

Funds holding: 6 [Q4 2023] → 6 (+0) [Q1 2024]

0% less ownership

Funds ownership: 0.77% [Q4 2023] → 0.77% (-0%) [Q1 2024]

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

Research analyst outlook

3 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$5
286%
upside
Avg. target
$5
286%
upside
High target
$5
286%
upside

3 analyst ratings

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Vernon Bernardino
286%upside
$5
Buy
Reiterated
5 Jun 2024
HC Wainwright & Co.
Vernon Bernardino
286%upside
$5
Buy
Reiterated
15 May 2024
HC Wainwright & Co.
Vernon Bernardino
286%upside
$5
Buy
Maintained
2 Apr 2024

Financial journalist opinion